Nuvalent stock reacts to oncology pipeline and recent returns

Nuvalent (NUVL), a clinical-stage cancer drug developer, has drawn attention after a run of strong recent returns, including about 55% over the past year and very large 3 year gains.

With a market value near US$7.0b and a last close of US$123.25, the stock now reflects expectations around its zero revenue profile, ongoing losses of US$450.074m, and multiple oncology programs in clinical trials.

The recent 39.3% 1 day share price return, alongside a 22.2% year to date share price return and a 181.7% three year total shareholder return, suggests momentum around Nuvalent is building as investors reassess its oncology pipeline and risk profile.

If you are looking beyond a single oncology stock and want to see what else is gaining attention in the sector, now is a good time to scan 39 healthcare AI stocks

With zero revenue, ongoing losses of US$450.074m and a market cap around US$7.0b, Nuvalent is already priced as a high expectation oncology stock. Investors might therefore ask whether there is still a buying opportunity here or whether the market has fully priced in future growth.

Discounted cash flow points to a wide valuation gap

Nuvalent last closed at $123.25, while the SWS DCF model estimates the value of its future cash flows at $655.39 per share, implying a large gap between price and modelled fair value.

The SWS DCF model projects future cash flows for the business and then discounts them back to today using a required rate of return. This aims to reflect the present value of those future streams in a single per share number.

For a clinical-stage biotech like Nuvalent, with zero current revenue and reported losses of $450.074m, this type of approach leans heavily on assumptions about future oncology trial progress, eventual commercialization, and the timing and scale of potential cash inflows rather than current earnings.

Result: DCF Fair value of $655.39 (UNDERVALUED)

However, this depends on unproven oncology assets. As a result, any clinical setback or slower than expected trial progress could quickly challenge the current valuation gap.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another view using P/B and market comparisons

While the SWS DCF model points to a large gap between price and modelled fair value, the picture changes when you look at Nuvalent’s P/B ratio. The stock trades at 8.3x book value, compared with 4.1x for peers and 2.4x for the broader US Biotechs industry.

That kind of premium suggests investors are already paying up for Nuvalent’s pipeline and future growth story. This raises the question of how much room is left if expectations cool or sentiment on clinical risk shifts.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Nuvalent for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 46 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment around Nuvalent split between opportunity and risk, it makes sense to look through the data yourself and decide quickly where you stand. To help frame that view, start by weighing the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Nuvalent has your attention, do not stop here. Use these focused stock ideas to quickly widen your watchlist and avoid missing other compelling opportunities.

• Target higher potential income by scanning for companies with stronger yields and resilience using the 9 dividend fortresses.
• Spot opportunities with more appealing pricing and quality by working through the 46 high quality undervalued stocks.
• Strengthen your watchlist by focusing on sturdier finances and fundamentals through the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.